Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.
$6.65+4.40%
报价 2026-11-06
市值
$241.3M
EV
$192.3M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -78.9%
$5.10$31.57
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| EVMNFunctional Brands, Inc. Common Stock | $241.3M | +4.4% | -48.5% | 100% | – | – | – | |
| LGNDLigand Pharmaceuticals, Inc. | $6.12B | +2.4% | +8.0% | 97.5% | 31.8x | 21.8x | 124.3x | |
| ZYMEZymeworks Inc. | $2.13B | +3.1% | – | 98.4% | – | – | – | |
| FTREFortrea Holdings Inc. | $2.08B | +7.3% | -4.4% | 17.1% | – | 34.8x | 12.5x | |
| OABIOmniAb, Inc. | $733.7M | +4.1% | +58.0% | 63.6% | – | – | 312.2x | |
| CLYMClimb Bio, Inc. | $591M | +16.0% | – | 0% | – | – | – | |
| ARTVArtiva Biotherapeutics, Inc. | $202.9M | +0.5% | -100.0% | 0% | – | – | – | |
| CDXSCodexis, Inc. | $118.3M | +5.9% | +10.1% | 79.5% | – | – | – | |
| EYPTEyePoint Pharmaceuticals, Inc. | $30.2M | +1.2% | -95.0% | 41.8% | – | – | – | |
| 同行中位数 | – | – | +1.8% | 52.7% | 31.8x | 28.3x | 124.3x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。